Table 5.
CR and 1-y survival by mutational status and treatment arm
| Mutation | n (%; 95% CI) of patients | Fisher’s exact P (2 sided) | |
|---|---|---|---|
| Arm A: decitabine (n = 56) | Arm B: decitabine + bortezomib (n = 62) | ||
| ASXL1 | n = 14 | n = 13 | |
| CR* | 2 (14; 2-43) | 2 (15; 2-45) | 1.0 |
| 1-y survival† | 6 (43; 23-79) | 7 (54; 33-89) | .71 |
| No ASXL1 | n = 42 | n = 49 | |
| CR* | 8 (19; 9-34) | 13 (27; 15-41) | .46 |
| 1-y survival† | 16 (42; 29-60) | 23 (47; 35-63) | .52 |
| DNMT3A | n = 9 | n = 14 | |
| CR* | 1 (11; 0-48) | 3 (21; 5-51) | 1.0 |
| 1-y survival† | 3 (33; 7-70) | 7 (50; 23-77) | .67 |
| No DNMT3A | n = 47 | n = 48 | |
| CR* | 9 (19; 9-33) | 12 (25; 14-40) | .62 |
| 1-y survival† | 19 (40; 26-56) | 23 (48; 33-63) | .54 |
| IDH2 | n = 8 | n = 9 | |
| CR* | 2 (25; 3-65) | 2 (22; 3-60) | 1.0 |
| 1-y survival† | 5 (63; 24-91) | 7 (78; 40-97) | .62 |
| No IDH2 | n = 48 | n = 53 | |
| CR* | 8 (17; 7-30) | 13 (25; 14-40) | .46 |
| 1-y survival† | 17 (35; 22-51) | 23 (43; 30-58) | .42 |
| NPM1 | n = 6 | n = 11 | |
| CR* | 2 (33; 4-78) | 3 (27; 6-61) | 1.0 |
| 1-y survival† | 3 (50; 12-88) | 7 (64; 31-89) | .64 |
| No NPM1 | n = 50 | n = 51 | |
| CR* | 8 (16; 7-29) | 12 (24; 13-37) | .46 |
| 1-y survival† | 19 (38; 25-53) | 23 (45; 31-60) | .55 |
| RUNX1 | n = 9 | n = 10 | |
| CR* | 2 (22; 3-60) | 1 (10; 0-45) | .58 |
| 1-y survival† | 5 (56; 21-86) | 5 (50; 19-81) | 1.0 |
| No RUNX1 | n = 47 | n = 52 | |
| CR* | 8 (17; 8-31) | 14 (27; 67-41) | .33 |
| 1-y survival† | 17 (36; 23-51) | 25 (48; 34-62) | .31 |
| TET2 | n = 8 | n = 12 | |
| CR* | 1 (13; 0-53) | 3 (25; 5-57) | .62 |
| 1-y survival† | 3 (38; 9-76) | 6 (50; 21-79) | .67 |
| No TET2 | n = 48 | n = 50 | |
| CR* | 9 (19; 9-33) | 12 (24; 13-38) | .63 |
| 1-y survival† | 19 (40; 26-55) | 24 (48; 34-63) | .42 |
| TP53 | n = 14 | n = 12 | |
| CR* | 3 (21; 5-51) | 2 (17; 2-48) | 1.0 |
| 1-y survival† | 3 (27; 11-66) | 2 (17; 5-59) | 1.0 |
| No TP53 | n = 42 | n = 50 | |
| CR* | 7 (17; 7-31) | 13 (26; 15-40) | .32 |
| 1-y survival† | 19 (47; 34-65) | 28 (56; 44-72) | .40 |
*
Binomial estimate for subgroups with ≤10 patients in a comparison.
†
Kaplan-Meier estimate.